跳转至内容
Merck
CN

1270480

USP

FTY720

United States Pharmacopeia (USP) Reference Standard

登录查看公司和协议定价

别名:
2-氨基-2- [2-(4-辛基-苯基)-乙基]-丙烷-1,3-二醇 盐酸盐, 芬戈莫德 盐酸盐
经验公式(希尔记法):
C19H33NO2 · HCl
分子量:
343.93
UNSPSC代码:
41116107
NACRES:
NA.24

生物来源

synthetic

Agency

USP

API类

fingolimod

形式

powder

制造商/商品名称

USP

储存条件

protect from light

颜色

white

溶解性

DMSO: soluble
ethyl acetate: soluble
water: soluble

应用

pharmaceutical

储存温度

2-8°C

InChI

1S/C19H33NO2.ClH/c1-2-3-4-5-6-7-8-17-9-11-18(12-10-17)13-14-19(20,15-21)16-22;/h9-12,21-22H,2-8,13-16,20H2,1H3;1H

InChI key

SWZTYAVBMYWFGS-UHFFFAOYSA-N

正在寻找类似产品? 访问 产品对比指南

一般描述

Fingolimod Hydrochloride (fingolimod HCl), an S1P-receptor modulator, belongs to the class of synthetic glucocorticoid steroid drugs.
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets, have been developed and issued under the Authority of the issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

应用

Fingolimod Hydrochloride USP reference standard may be used to quantify the analyte in gel, capsule and other pharmaceutical formulations, active pharmaceutical ingredient (API) and pharmaceutical dosage forms by liquid chromatography (LC) based techniques.

生化/生理作用

FTY720是一种免疫调节药物以及1-磷酸鞘氨醇(S1P)受体的调节剂。 鞘氨醇激酶对FTY270的磷酸化可导致S1P1R的内化,从而螯合淋巴结中的淋巴细胞,阻止它们参与自身免疫反应。 临床上,它已被批准用于治疗多发性硬化症(MS)。研究显示其可通过抑制S1PR阻断和逆转紫杉醇诱导的化疗诱导的周围神经病变(CIPN),并可抑制小鼠脑海马中组蛋白脱乙酰酶的活性,从而调节记忆。

分析说明

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

其他说明

Sales restrictions may apply.

象形图

Health hazard

警示用语:

Warning

危险声明

预防措施声明

危险分类

STOT RE 2

靶器官

Immune system

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable


分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

A randomized, open-label study assessing the bioequivalence of two formulations of Fingolimod 0.5 mg in healthy subjects
Tanguay M, et al.
AAPS Open, 4(1), 3-3 (2018)
Fingolimod Hydrochloride
Fingolimod Hydrochloride USP Monograph; USP42-NF37:United States Pharmacopeia and National Formulary
United States Pharmacopeia, 43(6)(1), 1849-1849 (2020)
Rapid determination of fingolimod hydrochloride-related Substances and degradation products in API and pharmaceutical dosage forms by use of a stability-indicating UPLC method
Rajan N and Basha KA
Chromatographia, 77(21-22), 1545-1552 (2014)
Solubility of dexamethasone in supercritical carbon dioxide
Chim RB, et al.
Journal of Chemical and Engineering Data, 57(12), 3756-3760 (2012)
Sphingosine 1-phosphate receptor 1 as a useful target for treatment of multiple sclerosis
Chiba K and Adachi K
Pharmaceuticals (Basel, Switzerland), 5(5), 514-528 (2012)

相关内容

High-Performance Liquid Chromatography method ensures total chromatographic purity analysis of Fingolimod Hydrochloride, offering rapid accuracy.

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门